Company: SNY
Filing Date: 2025-02-13
Form Type: 20-F
Source: 0001121404-25-000010
Chunk: 436

Company: Sanofi
Filing Date: 2025-02-13
Form: 20-F
Chunk 436
---
217 |                   -121 |               -337 |             -458 |                                  -241 |                                   -90 |                                  -120 |

| SANOFIFORM 20-F2024 | F-75 |

| NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS |

Objectives of the use of derivative financial instruments Sanofi uses derivative instruments to manage operating exposure to movements in exchange rates, and financial exposure to movements in interest rates and exchange rates (where the debt or receivable is not contracted in the functional currency of the borrower or lender entity). On occasion, Sanofi uses equity derivatives in connection with the management of its portfolio of equity investments. Sanofi performs periodic reviews of its transactions and contractual agreements in order to identify any embedded derivatives, which are accounted for separately from the host contract in accordance with IFRS 9. Sanofi had no material embedded derivatives as of December 31, 2024 , 2023 or 2022 . Counterparty risk For a description of counterparty risk, refer to “Item 11. — Quantitative and Qualitative Disclosures about Market Risk”. a) Currency derivatives used to manage operating risk exposures For a description of Sanofi’s objectives, policies and procedures for the management of operating foreign exchange risk, refer to “Item 11. — Quantitative and Qualitative Disclosures about Market Risk”. The table below shows operating currency hedging instruments in place as of December 31, 2024 , with the notional amount

translated into euros at the relevant closing exchange rate:

| December 31, 2024              |                |           | Of which derivatives designated ascash flow hedges |           |                              | Of which derivatives noteligible for hedge accounting |            |
|:-------------------------------|---------------:|----------:|:---------------------------------------------------|:----------|:-----------------------------|------------------------------------------------------:|-----------:|
| (€ million)                    | Notionalamount | Fairvalue | Notionalamount                                     | Fairvalue | Of whichrecognized in equity |                                        Notionalamount | Fair value |
| Forward currency sales         |          7,521 |       -67 | —                                                  | —         | —                            |                                                 7,521 |        -67 |
| of which US dollar             |          3,974 |       -59 | —                                                  | —         | —                            |                                                 3,974 |        -59 |
| of which Chinese yuan renminbi |            703 |        -5 | —                                                  | —         | —                            |                                                   703